Experimental treatment with sodium stibogluconate of hamsters infected with Leishmania (Leishmania) chagasi and Leishmania (Leishmania) amazonensis

Figueiredo, Elizabeth M. de; Silva, Jaime Costa e; Brazil, Reginaldo Peçanha

doi:10.1590/s0037-86821999000200012

Cited by 4 publications

(1 citation statement)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hamster is highly susceptible to dermotropic Leishmania infection and has been largely used as a model for visceral leishmaniasis (Goto and Lindoso, 2004; Dea-Ayuela et al 2007). The animal develops skin lesions when infected by one of the Viannia or Leishmania species including L. ( V. ) braziliensis (Brazil, 1976; Wilson et al 1979; Morais-Teixeira et al 2008), L. ( L. ) amazonensis (Figueiredo et al 1999), L. ( V .) guyanensis , L. ( V. ) panamensis (Rey et al 1990; Osorio et al 2003), L. ( V. ) lainsoni (Corrêa et al 2007) and L. ( V. ) peruviana (Gamboa et al 2008).…”

Section: Introductionmentioning

confidence: 99%

Golden hamster (Mesocricetus auratus) as an experimental model forLeishmania(Viannia)braziliensisinfection

et al. 2013

View full text Add to dashboard Cite

Leishmania (Viannia) braziliensis infection is a limiting factor for studying American tegumentary leishmaniasis (ATL). The golden hamster (Mesocricetus auratus) is a promising model because besides being highly susceptible to dermotropic Leishmania infection, the lesions are very similar to cutaneous leishmaniasis (CL) in humans. However, different Leishmania isolates or species and/or protocols have resulted in different outcomes, whereas no study has evaluated the reproducibility of L. braziliensis infection in this model. The natural history of L. braziliensis infection in 34 hamsters was evaluated by using a single parasite isolate in 8 independent experiments under similar experimental conditions. Clinical, histological and immunological analyses were performed. The hamsters presented skin ulcers similar to those observed in ATL. The intra-experiment lesion increment tended to show an intermediary variance. Histological analysis of infected skins showed granulomatous reaction, scarce amastigotes, and Schaumann's bodies. Blood lymphocytes proliferated in response to leishmanial antigens. The severity of the infection was positively correlated to spleen weight, and the titres of anti-Leishmania IgG antibodies. Our findings indicate that the hamster is an appropriate model for immunopathogenesis studies of CL caused by L. braziliensis, supporting its use in clinical, vaccine and chemotherapy experimental protocols.

show abstract

Section: Introductionmentioning

confidence: 99%

Golden hamster (Mesocricetus auratus) as an experimental model forLeishmania(Viannia)braziliensisinfection

et al. 2013

View full text Add to dashboard Cite

show abstract

Clinical and Laboratory Aspects of Leishmania Chemotherapy in the Era of Drug Resistance

Zilberstein

Ephros

2002

World Class Parasites

View full text Add to dashboard Cite

Treatment of visceral leishmaniasis (kala-azar): A decade of progress and future approaches

Murray¹

2000

International Journal of Infectious Diseases

View full text Add to dashboard Cite

In 1990, there was essentially one treatment regimen in use for visceral leishmaniasis (kala-azar) around the world: 20 to 28 days of daily injections of pentavalent antimony (Sb). During the past 10 years, however, new agents have been tested alone or in combination, in more than 50 studies carried out worldwide. This renewed clinical effort was spurred by a variety of factors, including the emergence of large-scale Sb unresponsiveness in India, where up to one-half of the world's cases of kala-azar now are found. As this new decade opens, the success of this clinical research effort is tangible: three additional, highly effective parenteral regimens now are available (amphotericin B, lipid formulations of amphotericin B, aminosidine), and an active oral agent, a long sought after objective in kala-azar, has been identified (miltefosine). This report reviews the evolution of treatment of visceral leishmaniasis, considers the interaction of the immune response and chemotherapy, highlights therapeutic successes and failures, examines advantages and disadvantages of current treatments, and looks at future therapeutic approaches to the management of this disseminated intracellular protozoal infection.

show abstract

Experimental treatment with sodium stibogluconate of hamsters infected with Leishmania (Leishmania) chagasi and Leishmania (Leishmania) amazonensis

Cited by 4 publications

References 1 publication

Golden hamster (Mesocricetus auratus) as an experimental model forLeishmania(Viannia)braziliensisinfection

Golden hamster (Mesocricetus auratus) as an experimental model forLeishmania(Viannia)braziliensisinfection

Clinical and Laboratory Aspects of Leishmania Chemotherapy in the Era of Drug Resistance

Treatment of visceral leishmaniasis (kala-azar): A decade of progress and future approaches

Contact Info

Product

Resources

About